Furthermore, several small molecule inhibitors, such as ibrutinib (Bruton tyrosine kinase inhibitor) (84), ABT-199 (Bcl-2 inhibitor) (85), and JQ-1 (bromodomain inhibitor) (86), has shown impressive potential for treating DLBCL patients. Here, BCL2 is linked to diffuse large B-cell lymphoma.